Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia
NCT00769912
Abortion
Marseille, France
View Trial DetailsNCT Number: NCT01799252
The effectiveness of antibiotic treatment at reducing post-abortion infection is unclear. The experiences of women prescribed routine antibiotics after medical abortion is missing from the existing evidence. This study seeks to add to the literature evidence of the side effects associated with antibiotic treatment that women experience and their adherence to prescribed regimens.
Looking for future studies?
Notify MeFemale
Observational
Feminist Women's Health Center, Atlanta, Georgia, United States
Medical abortion (MA) consists of administering medication, typically a combination of mifepristone and misoprostol, to induce an abortion without any invasive procedures. Early first trimester MA is effective1, highly acceptable to women, and safe. The risk of infection following medical abortion is small, at less than 1%. In rare circumstances, pelvic infection with clostridia bacteria following medical abortion has resulted in death. Since 2000, when mifepristone was registered in the United States, 8 such deaths have been recorded in the US.
Following the publication of case reports of four clostridium-associated deaths after medical abortion in 2005, the reproductive health community reacted swiftly. Medical abortion protocols were altered in an effort to curb these drastic and rapidly fatal infections. Antibiotic treatment, typically a seven-day course of doxycycline, has become widespread in the United States.
The effectiveness of antibiotic treatment at reducing post-abortion infection is unclear. The experiences of women prescribed routine antibiotics after medical abortion is missing from the existing evidence. This study seeks to add to the literature evidence of the side effects associated with antibiotic treatment that women experience and their adherence to prescribed regimens.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7-14 days following medical abortion
Compare the incidence rates of nausea between women who are prescribed a seven-day regimen of doxycycline to women who are not prescribed antibiotics following medical abortion
Time frame: 7-14 days following medical abortion
Document the self-reported adherence to antibiotic regimens following medical abortion
Time frame: 7-14 days following medical abortion
Compare the rates of nausea between women who take at least one doxycycline pill to women who do not take any doxycycline following medical abortion
Time frame: 7-14 days following medical abortion
Compare the rates of other (non-nausea) side effects between women who are prescribed a seven-day regimen of doxycycline to women who are not prescribed antibiotics following medical abortion
Time frame: 7-14 days following medical abortion
Compare the use of additional medication to treat side effects between women who take antibiotics and women who do not take antibiotics following medical abortion
Time frame: at time of filling prescription
Document the cost to women of antibiotics regimens following medical abortion
Gynuity Health Projects
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00769912
Abortion
Marseille, France
View Trial DetailsNCT02580175
Abortion
Asyut, Egypt
View Trial DetailsNCT05688228
Abortion
Bordeaux, France
View Trial DetailsNCT06178224
Abortion, Pregnancy Related
Tacoma, Washington, United States
View Trial Details